LATEST HIGHLIGHTS

Advance Online Publication

iPS-cells and tumorigenicity
Brief Communication by Miura et al.

The safety of induced pluripotent stem (iPS) cells seems to depend on how they were generated. Miura et al. examine the effects of the c-Myc transgene, tissue of origin and selection method on the tumor-forming propensity of iPS-cell derivatives.


Current Issue

Safer stem-cell therapies
Commentary by Carpenter et al.

Bringing therapies based on pluripotent stem cells from the lab to the clinic will require thorough testing for safety. Carpenter and colleagues discuss the issues that should be addressed to minimize the risks to patients.


Web Portal

Platform firms are coming back into favor, but they need to be created in the right way to succeed.


New!

SciBX - Ask your librarian to start a trial today!

SciBX: Science-Business eXchange is a weekly publication that identifies and analyses the most important translational research articles from over 40 journals. Find out which papers have real scientific and commercial potential, and why. Subscribe to SciBX and you won't miss the next big thing.

SciBX is now available in full-text, HTML format on the nature.com platform.
Recommend SciBX to your library today

For more information visit: www.nature.com/scibx/


Current Issue

Selective drug combinations
Article by Lehár et al.

Although combinations of drugs are often more potent than single agents, they are also believed to induce worse side effects. By screening >94,000 drug pairs in vitro, Lehár et al. show that synergistic combinations tend to be more selective than single drugs and are therefore unlikely to cause synergistic side effects.


Current Issue

Single-molecule transcriptomics
Article by Lipson et al.

Lipson et al. profile the yeast transcriptome using single-molecule sequencing. This approach avoids the inherent biases of the digestion, ligation and amplification steps in alternative methods based on microarrays or other sequencing technologies.


Impact Factor

The 2007 impact factor for Nature Biotechnology is 22.8, according to the ISI Journal Citation Reports. This places Nature Biotechnology first among primary research journals in the field of biotechnology.


Special Section

Now that ~1,000 microbial genomes have been sequenced, Kyrpides reflects on the past decade of microbial genomics and proposes solutions to remaining challenges in the field.



Extra navigation


natureproducts


ADVERTISEMENT